Ovarian tumor antigens: a new potential for therapy.

Abstract	A murine tumor-associated alpha-globulin was identified by immunofluorescence, cytotoxicity, and immunoelectrophoresis. The antiserum resulting from heterologous immunization with the segregated antigen was tolerated in multiple injections and was therapeutic; host cell participation by macrophages and lymphocytes led to the therapeutic result. Investigation of human ovarian carcinoma demonstrated an alpha-globulin which shares antigenic specificity with other tumor-associated antigens. The successful scanning of a tumor mass with a heterologous antibody directed against a tumor-associated antigen demonstrated the feasibility of applying these techniques to clinical cancer.
Authors	S E Order, J Thurnston, R Knapp
Journal	National Cancer Institute monograph (Natl Cancer Inst Monogr) Vol. 42 Pg. 33-43 (Oct 1975) ISSN: 0083-1921 [Print] United States
PMID	1234634 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References	Antigens, Neoplasm Immune Sera Lectins
Topics	Animals Antigens, Neoplasm (administration & dosage) Cytotoxicity Tests, Immunologic Female Immune Sera (pharmacology) Immunization, Passive Immunotherapy Lectins (pharmacology) Lymphocyte Activation Mice Mice, Inbred C3H Neoplasms, Experimental Ovarian Neoplasms (immunology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!